Gilead Sciences vs Iovance Biotherapeutics
Gilead Sciences (GILD) and Iovance Biotherapeutics (IOVA) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $206B
- Last close
- $166.43
- 12 months
- +33.1%
- Market value
- $3.19B
- Last close
- $6.90
- 12 months
- +216.5%
At a glance
- The biggest part of Gilead Sciences's revenue is Biktarvy (49%); at Iovance Biotherapeutics it is Amtagvi (83%).
- Gilead Sciences earns 71% of its revenue in the United States, Iovance Biotherapeutics 98%.
- By market value, Gilead Sciences ($206.4B) is about 65 times Iovance Biotherapeutics ($3.2B).
- Over the last 12 months Gilead Sciences's share price moved +33.1% and Iovance Biotherapeutics's +216.5%; against the S&P 500 that is +27.4 points and +210.8 points.
- In their last fiscal years Gilead Sciences kept 28.9% of revenue as net income and Iovance Biotherapeutics -148.4%.
- In the last 90 days insiders reported 0 open-market purchases at Gilead Sciences and 0 at Iovance Biotherapeutics; members of Congress disclosed 0 trades in Gilead Sciences and 0 in Iovance Biotherapeutics.
- Next results: Gilead Sciences Feb 8, 2027, Iovance Biotherapeutics Feb 22, 2027.
How each one makes money: Gilead Sciences revenue
Share prices on one chart
Gilead Sciences and Iovance Biotherapeutics, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Gilead Sciences GILDNASDAQ · Biotechnology | Iovance Biotherapeutics IOVANASDAQ · Biological Products, (No Diagnostic Substances) | |
|---|---|---|
| Size and profitability | ||
| Market value | $206B | $3.19B |
| Revenue, last fiscal year | $29.4B | $264M |
| Net income, last fiscal year | $8.51B | −$391M |
| Net marginNet income as a share of revenue | 28.9% | -148.4% |
| Free cash flow | ||
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Gilead Sciences against
Common questions
How is Gilead Sciences different from Iovance Biotherapeutics?
Gilead Sciences (GILD) is in Biotechnology on NASDAQ, with $29.4B of revenue in its last fiscal year and a net margin of 28.9%. Iovance Biotherapeutics (IOVA) is in Biological Products, (No Diagnostic Substances) on NASDAQ, with $264M of revenue in its last fiscal year and a net margin of -148.4%. The biggest part of Gilead Sciences's revenue is Biktarvy (49%); at Iovance Biotherapeutics it is Amtagvi (83%). Gilead Sciences earns 71% of its revenue in the United States, Iovance Biotherapeutics 98%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Gilead Sciences and Iovance Biotherapeutics compare in size?
Gilead Sciences has the larger market value: Gilead Sciences $206B and Iovance Biotherapeutics $3.19B, at the last close.
Whose share price rose more over the last 12 months, GILD or IOVA?
Over the last 12 months Gilead Sciences moved +33.1% and Iovance Biotherapeutics +216.5%. Past price moves say nothing about the future.
Which has had more insider buying, Gilead Sciences or Iovance Biotherapeutics?
Since 2006, Iovance Biotherapeutics insiders reported 31 open-market purchases against 8 for Gilead Sciences. These are counts of what was filed, not a view on either stock.
Do members of Congress trade GILD or IOVA?
In the last 12 months, members of Congress disclosed 4 trades in Gilead Sciences (GILD) and 0 in Iovance Biotherapeutics (IOVA).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Gilead Sciences pageIovance Biotherapeutics pageRare insider trades this weekAll comparisons
https://oqro.io/compare/gild-vs-iova







